Shahla Shahbazi

Dr. Shahla Shahbazi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Microbial Drug Resistance
Verified
Journal Article
Closed access
MMMajid Taati Moghadam
Majid Taati Moghadam
MMMehrnaz Mirzaei
Mehrnaz Mirzaei
MMMozhdeh Fazel Tehrani Moghaddam
Mozhdeh Fazel Tehrani Moghaddam
SBSajad Babakhani
Sajad Babakhani
OYOmid Yeganeh
Omid Yeganeh
SSShahla Shahbazi
Shahla Shahbazi
Escherichia coli ST131 is one of the high-risk multidrug-resistant clones with a global distribution and the ability to persist and colonize in a variety of niches. Carbapenemase-producing E. coli ST131 strains with the ability to resist last-line antibiotics ( i.e. , colistin) have been recently considered a significant public health. Colistin is widely used in veterinary medicine and therefore, colistin-resistant bacteria can be transmitted from livestock to humans through food. There are several mechanisms of resistance to colistin, which include chromosomal mutations and plasmid-transmitted mcr genes. E. coli ST131 is a great model organism to investigate the emergence of superbugs. This microorganism has the ability to cause intestinal and extraintestinal infections, and its accurate identification as well as its antibiotic resistance patterns are vitally important for a successful treatment strategy. Therefore, further studies are required to understand the evolution of this resistant organism for drug design, controlling the evolution of other nascent emerging pathogens, and developing antibiotic stewardship programs. In this review, we will discuss the importance of E. coli ST131, the mechanisms of resistance to colistin as the last-resort antibiotic against resistant Gram-negative bacteria, reports from different regions regarding E. coli ST131 resistance to colistin, and the most recent therapeutic approaches against colistin-resistance bacteria.

13 July 2025 in Medcomm
Verified
Journal Article
Open access
MMMajid Taati Moghadam
Majid Taati Moghadam
SMSamane Mohebi
Samane Mohebi
RSRaheleh Sheikhi
Raheleh Sheikhi
MHMeysam Hasannejad‐Bibalan
Meysam Hasannejad‐Bibalan
SSShahla Shahbazi
Shahla Shahbazi
SNShadman Nemati
Shadman Nemati
The rapid global spread of antibiotic‐resistant bacteria presents a growing public health crisis, threatening the efficacy of existing antimicrobial treatments. As traditional antibiotics become increasingly ineffective, alternative therapies such as bacteriophages and endolysins have gained renewed scientific and clinical interest. These biological agents, naturally derived from bacteriophage life cycles, exhibit potent and selective antibacterial activity, especially against multidrug‐resistant pathogens. Despite decades of research, the clinical translation of phage and endolysin therapies remains limited due to regulatory, delivery, and stability challenges. This review provides a comprehensive overview of the mechanisms, advantages, and limitations of both bacteriophages and endolysins, including their structure, mode of action, and interaction with bacterial hosts. Particular attention is given to combination therapies, where synergistic effects have been observed–especially in biofilm‐associated infections. We also explore the latest findings from preclinical studies, clinical trials, and compassionate‐use cases, with an emphasis on genetically engineered and synthetic variants that enhance therapeutic potential. Furthermore, we discuss manufacturing challenges, regulatory barriers, and future directions such as personalized phage therapy and engineered endolysins. By synthesizing current knowledge, this review highlights the academic and translational significance of phage and endolysin‐based approaches in combating antibiotic‐resistant infections.

8 November 2023 in International Immunopharmacology
Verified
Journal Article
Closed access
SSShahla Shahbazi
Shahla Shahbazi
MHMehri Habibi
Mehri Habibi
FBFarzad Badmasti
Farzad Badmasti
SSSamira Sabzi
Samira Sabzi
MFMehdi Farokhi
Mehdi Farokhi
MKMohammad Reza Asadi Karam
Mohammad Reza Asadi Karam

9 September 2022 in Journal of Basic Microbiology
Verified
Journal Article
Closed access
SSShahla Shahbazi
Shahla Shahbazi
Ali ShivaeeAli Shivaee
Ali Shivaee
MNMarzieh Nasiri
Marzieh Nasiri
MMMaryam Mirshekar
Maryam Mirshekar
SSSamira Sabzi
Samira Sabzi
OSOmid K. Sariani
Omid K. Sariani

1 April 2024 in New Microbes and New Infections
Verified
Journal Article
Open access
MMMaryam Mirshekar
Maryam Mirshekar
RZRezvan Golmoradi Zadeh
Rezvan Golmoradi Zadeh
MMMajid Taati Moghadam
Majid Taati Moghadam
SSShahla Shahbazi
Shahla Shahbazi
FJFaramarz Masjedian Jazi
Faramarz Masjedian Jazi
Antibiotic resistance in Klebsiella pneumoniae isolates, particularly resistance to colistin, has become a growing concern. This study seeks to investigate the upregulation of specific genes (pmrA, pmrB, pmrC, phoQ, phoP, and arnT) that contribute to colistin resistance in K. pneumoniae isolates collected from human clinical samples in Tehran, Iran. Thirty eight K. pneumoniae isolates were obtained and subjected to antibiotic susceptibility testing, as well as evaluation for phenotypic AmpC and ESBL production according to CLSI guidelines. The investigation of antibiotic resistance genes was conducted using polymerase chain reaction (PCR), whereas the quantification of colistin resistance related genes expressions was performed via Real-Time PCR. The highest and lowest antibiotics resistance were observed for cefotaxime 33 (86.8%) and minocycline 8 (21.1%), respectively. Twenty-four (63.2%) and 31 (81.6%) isolates carried AmpC and ESBLs, respectively. Also, antibiotic resistance genes containing blaNDM, blaIMP, blaVIM, blaSHV, blaTEM, blaCTXM, qnrA, qnrB, qnrS, and aac(6')-Ib were detected in K. pneumoniae isolates. Only 5 (13.1%) isolates were resistant to colistin and the MIC range of these isolates was between 4 and 64 μg ml−1. Upregulation of the pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes was observed in colistin-resistant isolates. The colistin-resistant isolates were found to possess a simultaneous presence of ESBLs, AmpC, fluoroquinolone, aminoglycoside, and carbapenem resistant genes. This study reveals escalating antibiotic resistance in K. pneumoniae, with notable coexistence of various resistance traits, emphasizing the need for vigilant surveillance and innovative interventions.

26 October 2023 in Future Microbiology
Verified
Journal Article
Closed access
MRMohammad Rahimzadeh
Mohammad Rahimzadeh
SSShahla Shahbazi
Shahla Shahbazi
SSSamira Sabzi
Samira Sabzi
MHMehri Habibi
Mehri Habibi
MKMohammad Reza Asadi Karam
Mohammad Reza Asadi Karam
Aims: To determine the antibiotic resistance and genetic diversity of Pseudomonas aeruginosa isolates. Methods: The antibiotic resistance, genetic diversity and the conjugate transformation among P...